Same-day breast pathology results using open-top light-sheet microscopy for image-guided core needle biopsies
Ended Project Grant Awarded Last action
- Award ID
- R41CA261263
- Recipient
-
Alpenglow Biosciences, Inc. UEI DVN2AF9A1YV3
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,593,217
Award facts
- Assistance listing
- 93.394 Cancer Detection and Diagnosis Research
- Completion date
- Originally
- Funding
-
- $1,194,912.49 Federal
- $398,305.00 Non-federal
- Place of performance
- Seattle, WA 98195, USA
Award details come from USAspending.gov.
Description
- Abstract
- (300 words maximum) each year, over 700 women undergo an image-guided core needle biopsy (CNB) to evaluate a suspicious breast finding at the seattle cancer care alliance, with only about 30% biopsies yielding malignancy. Typical turnaround time for determination of the presence or absence of cancer from cnbs is three to five business days, and this waiting time can lead to avoidable anxiety and delays in management. Our team has pioneered the use of open-top light-sheet microscopy (OTLS), which is a slide-free fluorescence imaging technique that enables rapid, large area scanning of fresh tissue. A preliminary study using excised 1 CM2 pieces of fresh breast tissue showed that OTLS imaging can provide diagnostic quality images in under 10 minutes. We hypothesize that OTLS evaluation of CNB breast tissue specimens will provide an accurate determination of malignancy VS. No malignancy within 30 minutes of obtaining breast core specimens. We will test this hypothesis by optimizing evaluation of CNB samples with OTLS using breast cancers that have been excised surgically and then testing its accuracy in a small clinical trial of 40 women. If successful, our approach could allow women with concerning breast imaging findings to have a complete imaging and pathology workup in the same day, leading to reassurance in the majority of women and earlier triage to appropriate care in those with breast cancer. Furthermore, wider application of this technology could allow for more accurate whole-specimen evaluation of biomarkers of disease, such as quantification of tumor infiltrating lymphocytes, and more elegant radiology-pathology correlation studies that could advance the emerging fields of radiomics and pathomics.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | -$3 | $0 | |
| Amendment | $398,305 | $0 | |
| Amendment | $398,305 | $0 | |
| Original award | $398,305 | $398,305 |
Quick answers
Who received award R41CA261263?
R41CA261263 was awarded to Alpenglow Biosciences, Inc. by National Cancer Institute (National Institutes of Health) on July 1, 2021.
How much is award R41CA261263 worth?
$1,593,217 has been obligated on R41CA261263: $1,194,912 in federal funding and $398,305 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award